PubMed · 7189428
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1980-02-23. Lumbar puncture.. https://pubmed.ncbi.nlm.nih.gov/7189428/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Synthetic 1-deamino-8-D-arginine-vasopressin (DDAVP) is used in the management of diabetes insipidus (DI). We conducted a systematic literature review of DDAVP use during pregnancy, with particular attention to its safety for both mother and infant. Studies were identified through Ovid MEDLINE from 1976 to July 1997 using the combined terms "desmopressin," "DDAVP," and "pregnancy". Review articles and published letters were also explored. One hundred one articles were retrieved, of which 20 met all the inclusion criteria. Included in the 20 articles were 53 cases with the use of DDAVP for the management of DI. The therapeutic daily dose of DDAVP was approximately 29 micrograms intranasally (range 7.5-100 micrograms), with adequate DI control observed. Three of 14 women with sufficient information developed preeclampsia, a nonsignificant difference from the expected rate of 5 percent (the Fisher exact test, 2-P = .08). The mode of delivery was defined for 22 cases, with 16 uneventful vaginal births, and six cesarean delivery. There was no evidence of a drug interaction among the five women who received both DDAVP and intravenous oxytocin. Information was available on 49 live births born to DI mothers on DDAVP. The mean gestational age at delivery was 37.4 weeks (SD 1.3 weeks), with an estimated mean birth weight of 2963.8 gm (range 2000-4420 gm). Forty-three offspring were reported as healthy (event rate 87.8 percent; 95 percent CI 77.2-95.3 percent). Of the remaining six infants, one developed DI at 18 months of age; a second was under 2500 gm at birth, but survived; the third developed hypotonia and failure to thrive at 21 months, two others had Down syndrome; and the sixth died of severe cardiac anomalies. Similar data were seen among the 41 infants whose mothers had used DDAVP throughout pregnancy. In conclusion, DDAVP use during pregnancy seems to be safe for both mother and child. Delivery does not seem to be augmented by its use, nor are there likely any associated adverse neonatal effects. A large database of DDAVP use during pregnancy is needed to confirm these findings.
Explore the source record for details and available documents.
This survey describes the evolution of our concept of monosymptomatic bedwetting over the last decades. It takes you briefly through psychology and enuresis. The minor role of bladder pathology is described ending up with focusing on the mismatch between bladder capacity at night-time and urine production. Monosymptomatic bedwetting should currently be regarded as an umbrella diagnosis allocated to children where daytime urinary problems have been excluded. Within the diagnosis of monosymptomatic bedwetting we can nowadays identify at least two groups. One is related to children who have a large night-time urine production and a normal bladder capacity, and the other is related to children who have a large night-time production, but a bladder capacity too small for the normal urine production. The genetic aspects are currently investigated. The results and this kind of research will probably end up in a further subgrouping.